Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.41 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PGD | P52209 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153718 | 0.86 | LMNA (0.67) | LMNASMN1; SMN2ALOX15MMP12CYP1A2 | |
| SCHEMBL10043022 | 0.84 | SMN1; SMN2 (0.41) | LMNASMN1; SMN2ALOX15MMP12GABRR1 | |
| SCHEMBL13684596 | 0.84 | — | — | |
| SCHEMBL28047126 | 0.83 | SMN1; SMN2 (0.40) | LMNASMN1; SMN2ALOX15MMP12CYP1A2 | |
| SCHEMBL10414980 | 0.80 | LMNA (0.60) | LMNASMN1; SMN2ALOX15MMP12CYP1A2 | |
| SCHEMBL6540754 | 0.79 | — | — | |
| SCHEMBL14262888 | 0.79 | CACNA2D1 (0.42) | LMNASMN1; SMN2ALOX15GABRR1CACNA2D1 | |
| SCHEMBL4923280 | 0.78 | LMNA (0.58) | LMNASMN1; SMN2ALOX15MMP12CYP1A2 | |
| SCHEMBL4928056 | 0.78 | LMNA (0.58) | LMNASMN1; SMN2ALOX15MMP12CYP1A2 | |
| SCHEMBL4923275 | 0.78 | LMNA (0.58) | LMNASMN1; SMN2ALOX15MMP12CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7777071-B2 | Production of carnitine conjugate intermediates | SSV THERAPEUTICS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090012160-A1 | Carnitine Conjugates As Dual Prodrugs, Methods Of Production And Uses Thereof | SSV THERAPEUTICS, INC. | 2009-01-08 | — | — | US | disclosed |
| US-7345190-B2 | Carnitine conjugates as dual prodrugs and uses thereof | SSV THERAPEUTICS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012160-A1 | Carnitine Conjugates As Dual Prodrugs, Methods Of Production And Uses Thereof | CPT1B, CRAT, CPT2 | LMNA 1078/4885SMN1; SMN2 628/4885ALOX15 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.